MOLECULAR THERAPY

Scope & Guideline

Exploring the frontiers of molecular biology and therapy.

Introduction

Explore the comprehensive scope of MOLECULAR THERAPY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore MOLECULAR THERAPY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1525-0016
PublisherCELL PRESS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2000 to 2024
AbbreviationMOL THER / Mol. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139

Aims and Scopes

Molecular Therapy is a journal dedicated to advancing the understanding and application of molecular therapeutics in various fields of medicine, particularly cancer, immunotherapy, and regenerative medicine. The journal aims to publish high-quality research that contributes to the development of novel therapeutic strategies and approaches.
  1. Cancer Therapeutics and Immunotherapy:
    The journal focuses on novel approaches to cancer treatment, including immunotherapy strategies such as engineered T cells and bispecific antibodies, as well as small molecule inhibitors targeting specific pathways related to tumor growth and metastasis.
  2. Metabolic and Inflammatory Disorders:
    Research on the therapeutic effects of various compounds in metabolic and inflammatory conditions is prominent, emphasizing the role of natural products, dietary components, and synthetic compounds in modulating metabolic pathways and inflammatory responses.
  3. Neuroprotection and Neuroinflammation:
    The journal includes studies on neuroprotective agents and the mechanisms underlying neuroinflammation, particularly in relation to neurodegenerative diseases and brain injuries.
  4. Molecular Mechanisms of Drug Action:
    A significant focus is placed on elucidating the molecular mechanisms of action of various therapeutic agents, including their effects on signaling pathways, gene expression, and cellular processes.
  5. Natural Products and Traditional Medicine:
    The exploration of bioactive compounds derived from natural sources for their therapeutic potentials is a key area, with studies investigating their mechanisms of action and clinical applications.
Recent publications in Molecular Therapy indicate several emerging themes that are gaining traction within the research community. These trends reflect current scientific interests and the evolving landscape of therapeutic development.
  1. Engineered Cell Therapies:
    There is a growing focus on engineered cell therapies, particularly in cancer treatment. This includes advancements in T cell receptor engineering and bispecific antibodies, which highlight innovative approaches to enhancing immune responses against tumors.
  2. Microbiome and Gut-Brain Axis:
    Research examining the role of gut microbiota and their metabolites in brain function and pathology is emerging, reflecting an interdisciplinary approach that links microbiology, neuroscience, and therapeutic interventions.
  3. Natural Compounds in Therapy:
    An increasing number of studies are investigating the therapeutic potentials of natural compounds, emphasizing their roles in modulating complex biological pathways and their potential applications in treating various diseases.
  4. Signaling Pathways in Disease Modulation:
    A trend towards understanding the intricate signaling pathways involved in disease mechanisms is evident, with a focus on how these pathways can be targeted for therapeutic intervention.
  5. Personalized Medicine Approaches:
    Emerging themes include the development of personalized medicine strategies, particularly in cancer therapeutics, where individual genetic and molecular profiles guide treatment decisions.

Declining or Waning

While Molecular Therapy continues to explore a wide range of impactful research areas, certain themes have shown a decline in prominence over recent years. This may reflect shifts in research focus or advancements in related fields.
  1. Traditional Pharmacology:
    Research centered around traditional pharmacological approaches has decreased, possibly due to the growing interest in novel molecular mechanisms and targeted therapies that offer more precise and effective treatment options.
  2. Basic Biochemical Studies:
    There is a noted reduction in purely biochemical studies that do not directly relate to therapeutic applications. The journal appears to favor research with clear clinical implications or translational potential.
  3. Animal Models of Disease:
    Although animal studies remain important, there seems to be a waning emphasis on basic animal model research without direct therapeutic relevance, as the focus shifts towards more innovative and applicable therapeutic strategies.

Similar Journals

CURRENT DRUG TARGETS

Navigating the Landscape of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Transforming cancer research into clinical solutions.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Journal of Natural Medicines

Fostering Excellence in Natural Therapeutic Research
Publisher: SPRINGER JAPAN KKISSN: 1340-3443Frequency: 4 issues/year

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

Current Molecular Pharmacology

Advancing the Frontiers of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Frontiers in Bioscience-Landmark

Shaping the Future of Bioscience Scholarship
Publisher: IMR PRESSISSN: 2768-6701Frequency: 12 issues/year

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.

MOLECULAR PHARMACOLOGY

Elevating Understanding of Molecular Drug Actions
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

MOLECULAR MEDICINE

Elevating the Standards of Peer-Reviewed Science
Publisher: SPRINGERISSN: 1076-1551Frequency: 1 issue/year

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

GENE THERAPY

Empowering Researchers with Cutting-Edge Discoveries
Publisher: SPRINGERNATUREISSN: 0969-7128Frequency: 12 issues/year

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

JOURNAL OF MOLECULAR MEDICINE-JMM

Transforming Research into Revolutionary Medical Solutions.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

CNS & Neurological Disorders-Drug Targets

Pioneering Discoveries in CNS Disorders and Drug Development
Publisher: BENTHAM SCIENCE PUBLISSN: 1871-5273Frequency: 8 issues/year

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.